Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity

References

• Newton R, Decicco C. Therapeutical potential and strategies for inhibiting tumor necrosis factor α. J Med Chem 1999;42:2295–314.
   PubMed Web of Science ®Google Scholar
• Sekut L, Connolly KM. Pathophysiology and regulation of TNF-α in inflammation. Drug News Perspect 1996;9:261–7.
   Web of Science ®Google Scholar
• Rink L, Kirchner H. Recent progress in the tumour necrosis factor-α field. Int Arch Allergy Immunol 1996;111:199–209.
   PubMed Web of Science ®Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumor necrosis factor-α from cells. Nature 1997;385:729–33.
   PubMed Web of Science ®Google Scholar
• Black RA, Fitzner JN, Sleath PR. Inhibitors of TNF-α secretion. United States Patent 5,594,106.
   Google Scholar
• Blobel CP. Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding. Inflamm Res 2002;51:83–4.
   PubMed Web of Science ®Google Scholar
• Xue C-B, He X, Roderick J, Corbett RL, Duan James JW, Liu R-O, et al. Rational design, synthesis and structure–activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: Lead optimization. Bioorg Med Chem Lett 2003;13:4299–304.
   PubMed Web of Science ®Google Scholar
• Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, et al. Reverse hydroxamate-based selective TACE inhibitors. Bioorg Med Chem Lett 2004;14:2897–900.
   PubMed Web of Science ®Google Scholar
• Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, et al. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors. Bioorg Med Chem Lett 2003;13:1487–90.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hegen M, Xu J, Keith JC Jr, Jin G, Du X, et al. Characterization of (2R, 3S)-2-({[4-(2-butynyloxy) phenyl] sulfonyl}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme. Int Immunopharmacol 2004;4:1845–57.
   PubMed Web of Science ®Google Scholar
• Xue C-B, Chen X-T, He X, Roderick J, Corbett RL, Ghavimi B, et al. Synthesis and structure–activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors. Bioorg Med Chem Lett 2004;14:4453–9.
   PubMed Web of Science ®Google Scholar
• Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, et al. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-α converting enzyme and matrix metalloproteinase inhibitors. J Med Chem 2004;47:6255–69.
   PubMed Web of Science ®Google Scholar
• Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 2005;87:249–63.
   PubMed Web of Science ®Google Scholar
• Lukacova V, Yufen Z, Kroll DM, Raha S, Comez D, Balaz S. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-α converting enzyme: implications for selectivity. J Med Chem 2005;48:2361–70.
   PubMed Web of Science ®Google Scholar
• Maskos K, Fernandez-Catalan C, Huber R, Bourenkov GP, Bartunik H, Ellestad GA, et al. Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme. Proc Natl Acad Sci USA 1998;95:3408–12.
   PubMed Web of Science ®Google Scholar
• Lovejoy B, Welch AR, Carr S, Luong C, Broka C, Hendricks RT, et al. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol 1999;6:217–21.
   PubMedGoogle Scholar
• Feng Y, Likos J, Zhu L, Woodward H, McDonald J, Stevens A, et al. 1H, 13C and 15N resonance assignments for a truncated and inhibited catalytic domain of matrix metalloproteinase-2. J Biomol NMR 2000;17:85–6.
   PubMed Web of Science ®Google Scholar
• Pavlovsky AG, Williams MG, Ye QZ, Ortwine DF, Purchase CF 2nd, White AD, et al. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Protein Sci 1999;8:1455–62.
   PubMed Web of Science ®Google Scholar
• Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM, Barratt DG, et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol 2002;319:173–81.
   PubMed Web of Science ®Google Scholar
• Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, et al. Matrix metalloproteinase inhibitors: a structure-activity study. J Med Chem 1998;41:199–206.
   PubMed Web of Science ®Google Scholar
• Yin B, Li Z, Yu S, Jiang X, Gong F, Xu Y, et al. Relationship between the increase of secretion of sTNF-α induced by lipopolysaccharides and the enhanced expression of TACE mRNA in HL-60 cells and adhesive cells from human spleen. J Tongji Med Univ 2001;21:265–7.
   PubMedGoogle Scholar
• Wang Z, Wang Y, Zhu K-L, Guo L-J, Yang Y-Z. Mechanism of three inhibitors of TACE in blocking the converting of pro-TNFα into sTNFα. J Huazhong Univ Sci Technol (Med Sci) 2003;23:458–61.
   Google Scholar
• Shen G, Zhou R. Modern Experimental Techniques in Immunology.Wuhan, China: Hubei Science and Technology Publishing Company, 1998:226–4.
   Google Scholar
• Zhao Y, Feng W-F, Yang Y-Z, Ling L-J, Chen R-S. Comparison of property of tumor necrosis factor-α converting enzyme (TACE) and some matrix metalloproteases (MMPs) in catalytic domain. J Huazhong Univ Sci Technol (Med Sci) 2006;26:637–9.
   PubMedGoogle Scholar